Evogene Ltd (EVGN) 2024 Q1 法說會逐字稿

Welcome to Evogene's first quarter results conference call. All participants are present in listen-only mode. Following management's formal presentation, we will open the call for the question-and-answer session. (Operator Instructions) as a reminder, this conference is being recorded May 23, 2024.

歡迎參加 Evogene 第一季業績電話會議。所有參與者都以僅監聽模式存在。在管理階層正式發言後，我們將開始問答環節。 （操作員說明）謹此提醒，本次會議的錄音時間為 2024 年 5 月 23 日。

Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's Management will constitute forward-looking statements that relate to future events. The presentation contains forward-looking statements relating to future events and Evogene Ltd.

在開始之前，我想提醒大家，Evogene 管理層在本次財報電話會議上發表的某些聲明將構成與未來事件相關的前瞻性聲明。本簡報包含與未來事件和 Evogene Ltd. 相關的前瞻性陳述。

The company may from time to time make other statements regarding our outlook or expectations for future financial or operating results and or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995 and other securities laws as amended.

本公司可能會不時就我們對未來財務或經營業績的展望或預期以及與我們有關或影響我們的其他事項發表其他聲明，這些聲明被視為1995 年美國私人證券訴訟改革法案和其他法案中定義的前瞻性聲明。

Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, plan, estimated, intend and potential or words of similar meaning. We're using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market size and milestones, pipeline as well as our capabilities and technology.

非歷史事實陳述的陳述可能被視為前瞻性陳述。此類前瞻性陳述可以透過使用「相信」、「期望」、「預期」、「應該」、「計劃」、「估計」、「打算」和「潛力」等詞語或類似含義的詞語來識別。當我們討論我們的價值驅動因素、商業化努力和時機、產品開發和發布、估計市場規模和里程碑、管道以及我們的能力和技術時，我們在本簡報中使用前瞻性陳述。

Such statements are based on current expectations. Estimates, projections and assumptions described or opinions about future events involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance and readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.

此類聲明基於當前的預期。所描述的估計、預測和假設或對未來事件的意見涉及某些難以預測的風險和不確定性，並且不能保證未來業績，請讀者註意，某些重要因素可能會影響公司的實際結果，並可能導致這些結果出現重大差異本簡報中可能做出的任何前瞻性陳述。

Therefore, actual future results, performance or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control.

因此，由於多種因素，未來的實際結果、績效或成就和趨勢可能與此類前瞻性陳述所表達或暗示的內容有重大差異，其中許多因素是我們無法控制的。

Including without limitation, the current war between Israel Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those described in greater detail in Evogene's annual report on Form 20-F and in other information Evogene files and furnishes with the Israel securities authority, and the US Securities and Exchange Commission, including those factors under the heading Risk Factors.

包括但不限於以色列哈馬斯和真主黨之間當前的戰爭以及以色列局勢的任何惡化，例如以色列北部邊境的進一步動員或升級，以及Evogene 的20-F 表格年度報告和其他報告中更詳細描述的情況Evogene 向以色列證券管理局和美國證券交易委員會提交並提供的信息，包括“風險因素”標題下的那些因素。

Except as required by applicable securities laws. We disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections, and assumptions.

除非適用的證券法要求。我們不承擔更新本簡報中包含的任何資訊的義務或承諾，也不承擔公開發佈為反映未來事件或預期、估計、預測和假設的發展或變更而可能做出的任何陳述的任何修訂結果的義務或承諾。

The information contained herein does not constitute a prospectus or other offering documents nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subscribe for any securities of Evogene or the company, nor shall the information or any part of it or the fact of its distribution form the basis of or be relied on in connection with any action contract commitment or relating thereto or to the securities of Evogene or the company.

本文所包含的資訊不構成招股說明書或其他發售文件，也不構成任何出售邀請或要約或任何購買或認購 Evogene 或公司任何證券的邀請或要約的任何招攬，也不構成任何出售邀請或要約的一部分。該資訊或其任何部分或其散佈事實構成任何訴訟合約承諾或與之相關或與Evogene 或公司證券相關的基礎或可依賴。

Trademarks included herein are the property of the owners thereof and are used for reference purposes only, such use should not be construed as an endorsement of our products or services.

本文所包含的商標是其所有者的財產，僅供參考，此類使用不應被解釋為對我們的產品或服務的認可。

On the call today will be Yaron Eldad, CFO of Evogene; and Yoash Zohar, CEO of Casterra. Additionally, a representative from each subsidiary will be present at the Q&A session.

今天參加電話會議的是 Evogene 財務長 Yaron Eldad；以及 Casterra 執行長 Yoash Zohar。此外，各子公司的代表將出席問答環節。

That said, I would now like to turn over the call to Ofer Haviv, President and CEO of Evogene. Mr. Haviv, please go ahead.

也就是說，我現在想將電話轉給 Evogene 總裁兼執行長 Ofer Haviv。哈維夫先生，請繼續。

Hello and good day. Everyone in today's conference call, I would like to start with the Evogene Group's financial and business highlights from the beginning of the year, continue with an overview of Evogene's activity and achievements since the beginning of 2024 and concluded with the achievements of our subsidiaries during that period,

你好，美好的一天。在今天的電話會議上，我想先介紹 Evogene 集團年初以來的財務和業務亮點，然後概述 Evogene 自 2024 年初以來的活動和成就，最後總結一下我們子公司在此期間取得的成就時期，

Following my part, Evogene CFO, [Yaron Eldad] will provide financial update of Q1 2024 activities. After that, we will open the Q&A session. Let us start with Evogene's Group financial and business highlights that took place from the beginning of this year.

接下來，Evogene 財務長 [Yaron Eldad] 將提供 2024 年第一季活動的財務更新。之後，我們將開始問答環節。讓我們從今年年初以來 Evogene 集團的財務和業務亮點開始。

In Q1 2024, our total revenue reached approximately $4.2 million compared to $0.6 million in Q1 2023. Looking ahead to the full year 2024 we anticipate continued revenue growth compared to the previous year. In Q1 2024, our loss was approximately $3.8 million compared to $7 million in Q1 2023, a decline of approximately 46%. Additionally, our projected cash use for 2024 excluding Biomica and Lavie Bio is approximately $8 million compared to $12.5 million in 2023, demonstrating a notable 36% decrease year-over-year.

2024 年第一季度，我們的總營收達到約 420 萬美元，而 2023 年第一季為 60 萬美元。展望 2024 年全年，我們預期營收將比前一年持續成長。2024 年第一季度，我們的虧損約為 380 萬美元，而 2023 年第一季為 700 萬美元，下降約 46%。此外，我們預計 2024 年（不包括 Biomica 和 Lavie Bio）的現金使用量約為 800 萬美元，而 2023 年為 1,250 萬美元，年比顯著下降 36%。

In Q1 2024 averages closedown Canonic's operation, resulting in an annualized saving of $1.5 million. On February 6, Evogene and Verb Biotics entered a collaboration agreement to invent probiotic innovation, aiming to produce sustainable microbial metabolites known to improve human-health and mentality.

2024 年第一季度，Canonic 的業務平均關閉，年化節省 150 萬美元。2 月 6 日，Evogene 和 Verb Biotics 達成了一項發明益生菌創新的合作協議，旨在生產已知可改善人類健康和心態的可持續微生物代謝物。

On April 2, Evogene and the Kitchen FoodTech Hub by the Strauss Group established Finally Foods, an AI driven company, aiming for established sustainable and efficient protein production in plants for the food sector. Evogene holds approximately a 40% stake in Finally Foods.

4 月 2 日，Evogene 和 Strauss Group 的 Kitchen FoodTech Hub 成立了人工智慧驅動型公司 Final Foods，旨在為食品業的工廠建立可持續、高效的蛋白質生產。Evogene 持有 Final Foods 約 40% 的股份。

The new company is funded by the Kitchen Hub and the Israeli Innovation authorities. These two new collaborations demonstrate the implementation of Evogene's business model in which we leverage our technology in new life science sector, not covered by our subsidiaries, benefiting from our partners' expertise in this new field.

新公司由廚房中心和以色列創新部門資助。這兩項新的合作展示了Evogene 商業模式的實施，在該模式中，我們將我們的技術運用到我們子公司未涵蓋的新生命科學領域，並受益於我們合作夥伴在這一新領域的專業知識。

Now I would like to highlight the main achievements made by Evogene subsidiaries from the beginning of this year Casterra recently announced agreement with African and Brazilian seed growers, securing an addition of approximately 900 tons of seeds are expected to fulfill all standing orders by the end of 2024. Biomica announced it will be presenting preliminary Phase I clinical trial results for its BMC128 microbiome therapeutics in oncology in a poster presentation at the 2024 ASCO Conference on June 3.

現在我想強調 Evogene 子公司今年年初以來的主要成就。Biomica 宣布將於 6 月 3 日在 2024 年 ASCO 會議上以海報形式展示其 BMC128 微生物組療法在腫瘤學方面的初步 I 期臨床試驗結果。

Lavie Bio received $2.5 million, the second half of an upfront payment from Corteva and announced a new collaboration agreement with Syngenta. Additionally, Lavie Bio announced an extension to its joint validation trial with Bayer for its biofungicide following successful laboratory and greenhouse testing. Marketing and sales efforts for Yalos, Lavie Bio's first commercial microbiome-based product are expanding in US and Canada with additional crops being added for treatment. Lavie Bio anticipates 2024 revenues for Yalos to increase compared to the previous year.

Lavie Bio 收到了 Corteva 預付款的後半部分 250 萬美元，並宣布與先正達達成新的合作協議。此外，在成功進行實驗室和溫室測試後，Lavie Bio 宣布延長與拜耳的生物殺菌劑聯合驗證試驗。Lavie Bio 首款以微生物組為基礎的商業產品 Yalos 的行銷和銷售工作正在美國和加拿大擴大，並增加了更多作物進行處理。Lavie Bio 預計 Yalos 2024 年的收入將比前一年增加。

AgPlenus announced a new collaboration agreement with Bayer. AgPlenus will be entitled to receive an apple payment, ongoing research funding, milestone payments and royalties based on future product sales. AgPlenus also achieved a milestone with Corteva as its existing collaboration agreement. I will provide more details on the achievement of each subsidiary later in the presentation.

AgPlenus 宣布與拜耳達成新的合作協議。AgPlenus 將有權獲得蘋果付款、持續研究經費、里程碑付款和基於未來產品銷售的特許權使用費。AgPlenus 與 Corteva 的現有合作協議也實現了里程碑。我將在稍後的演示中提供有關每個子公司所取得成就的更多詳細資訊。

Let us now move to the Evogene overview, and I will start by briefly reviewing our strategy and business model. The biggest challenge in developing life science-based product is at the beginning of the process in the discovery and optimization phases, finding the candidates that meet a long list of bit required criteria from huge quantity of potential candidates in order to reach a successful commercial product. It takes much time and resources and the profit of success, maybe slim, that's finding the needle in a.

現在讓我們進入 Evogene 概述，我將首先簡要回顧我們的策略和商業模式。開發基於生命科學的產品的最大挑戰是在發現和優化階段的過程開始時，從大量潛在候選者中找到滿足一長串位所需標準的候選者，以便獲得成功的商業產品。這需要大量的時間和資源，成功的利潤可能微乎其微，那就是找到針。

Evogene, pioneering a pioneering company in the field of life science-based products is aiming to revolutionize the industry. Our mission is to liberate dedicated big datasets with cutting edge computational Technology and Digital Athlete and deep life science, understanding addressing the discovery and optimization challenges to drive product innovation, securing our position as a leader in developing solution that advanced cumulative future.

Evogene 是生命科學產品領域的先鋒公司，旨在徹底改變該行業。我們的使命是透過尖端運算技術、數位運動員和深度生命科學解放專用大數據集，了解解決發現和優化挑戰以推動產品創新，確保我們在開發推動累積未來的解決方案方面的領導者地位。

So how do we make it happen? With investments of tens of millions of dollars in over a decade of intense work evident has created a groundbreaking platform called computational predictive biology, specifically platform, which integrates profound scientific knowledge with public and proprietary Big Data and AI technologies based on this platform.

那我們要如何實現這一目標呢？經過十多年的緊張工作，投入數千萬美元，顯然已經創建了一個名為計算預測生物學的突破性平台，特別是平台，它將深厚的科學知識與基於該平台的公共和專有的大數據和人工智慧技術相結合。

During past year, Evogene developed three innovative AI tech engines, addressing the main development challenges of three product categories. MicroBoost AI directs and accelerate the development of micro-based products, ChemPass AI for small molecule-based product and GeneRator AI for products based on genetic elements.

在過去的一年裡，Evogene開發了三個創新的人工智慧技術引擎，解決了三個產品類別的主要開發挑戰。MicroBoost AI 指導並加速基於微的產品的開發，ChemPass AI 用於基於小分子的產品，GeneRator AI 用於基於遺傳元件的產品。

The value proposition of our AI-driven tech engines stems from the efficient finding and optimization of the most promising candidates, therefore increasing the probability of success reaching a breakthrough product within a competitive timeframe and in a cost-efficient manner. Our three AI tech engines were structured to be compatible with the tremendous potential of all its market segment not limited to only one specific segment. This slide demonstrates the best varieties of market segments that can benefit from our technology.

我們人工智慧驅動的技術引擎的價值主張源於對最有前途的候選者的有效發現和優化，從而增加在有競爭力的時間範圍內以具有成本效益的方式成功實現突破性產品的可能性。我們的三個人工智慧技術引擎的結構與其所有細分市場的巨大潛力相容，而不僅限於某一特定細分市場。這張投影片展示了可以從我們的技術中受益的最佳細分市場品種。

Each tech engine is at the center of potential development of many product types addressing the needs of different life science industries in order to capture the value of our AI. tech engine, our business strategy is to establish the first collaborative partnership for life science product development department. We collaborate with our expert in specific fields that complements our technology. We adopted this approach to maximize the potential of our tech engine while reducing financial and development risks.

每個技術引擎都是許多產品類型潛在開發的中心，可以滿足不同生命科學產業的需求，以獲得人工智慧的價值。科技引擎，我們的經營策略是建立第一個生命科學產品開發部門的合作關係。我們與特定領域的專家合作，以補充我們的技術。我們採用這種方法是為了最大限度地發揮我們技術引擎的潛力，同時降低財務和開發風險。

Therefore, we formed partnerships through licensing or collaboration with companies positioning domain-specific knowledge such as pharmaceutical or as we back together, we will develop novel products aiming to full or partial ownership of all project completions.

因此，我們透過許可或與定位特定領域知識（例如製藥）的公司合作建立了合作夥伴關係，或者當我們重新團結起來時，我們將開發旨在實現所有專案完成的全部或部分所有權的新穎產品。

We believe this strategy holds the potential for groundbreaking innovations and significant financial gain gains for Evogene. This is a current snapshot of the status of our business model with Evogene owning four subsidiary companies finding additional market segments not covered by our subsidiary. We have collaboration with leading companies all working on developing innovative lifestyle products.

我們相信這項策略具有為 Evogene 帶來突破性創新和顯著財務收益的潛力。這是我們業務模式現狀的快照，Evogene 擁有四家子公司，尋找我們子公司未涵蓋的其他細分市場。我們與致力於開發創新生活方式產品的領先公司合作。

More specifically, we have two license agreements utilizing MicroBoost AI, one with our subsidiary Lavie Bio to develop ag-biological and the second was our subsidiary, Biomica to develop drugs based on the human microbiome. In addition, we established a collaboration with Verb Biotics to develop probiotic product, on which we announced this quarter, and I will elaborate on shortly. With respect to ChemPass AI, we had a license agreement with our subsidiary AgPlenus to develop ag-chemicals and the collaboration agreement with our subsidiary Biomica to develop drugs based on small molecules.

更具體地說，我們擁有兩份利用MicroBoost AI 的授權協議，一份是與我們的子公司Lavie Bio 合作開發農業生物製劑，另一份是與我們的子公司Biomica 合作開發基於人類微生物組的藥物。此外，我們與 Verb Biotics 建立了合作開發益生菌產品，我們在本季度宣布了這一消息，我將很快詳細介紹。關於 ChemPass AI，我們與子公司 AgPlenus 簽訂了開發農業化學品的授權協議，並與子公司 Biomica 簽訂了開發基於小分子的藥物的合作協議。

Last but not least with respect to GeneRator AI, we have a license agreement with our subsidiary, Casterra, for the development of elite castor seed varieties, a license agreement with Finally Foods for protein production in plant on which we announced this quarter, and I will elaborate on shortly. On top of Verb’s agreement with Colors Farms for improving condition traits and with the Horizon EU consortium for improving traits in canola. I would now like to provide additional details on the decisions concerning our subsidiary Canonic and the new engagement with Verb Biotics and Finally Foods.

最後但並非最不重要的一點是，關於GenRator AI，我們與我們的子公司Casterra 簽訂了一份許可協議，用於開發優質蓖麻種子品種，與Final Foods 簽訂了一份用於工廠蛋白質生產的許可協議，我們在本季度宣布了該協議，並且我稍後將詳細說明。除了 Verb 與 Colors Farms 就改善條件性狀達成協議，以及與 Horizo​​​​n EU 聯盟就改善油菜籽性狀達成協議外。我現在想提供有關我們子公司 Canonic 的決定以及與 Verb Biotics 和 Final Foods 的新合作的更多細節。

In Q1 2024, Evogene decided to cease operations of Canonic, which specialized in developing medical cannabis products due to the challenging market condition in the medical cannabis sector. This decision results in annualized savings of approximately $1.5 million, resorted we intend to allocate to area with greater growth potential such as funding Casterra's needs for ongoing capital. This decision highlights Evogene commitment to prevent resources management and strategic focus in response to evolving market conditions.

2024 年第一季度，由於醫用大麻領域充滿挑戰的市場狀況，Evogene 決定停止 Canonic 的業務，該公司專門開發醫用大麻產品。這項決定每年節省約 150 萬美元，我們打算分配給具有更大成長潛力的領域，例如為 Casterra 的持續資本需求提供資金。這項決定凸顯了 Evogene 對防止資源管理和策略重點以應對不斷變化的市場狀況的承諾。

At the beginning of February, Evogene and Verb Biotics entered a collaboration agreement to advance probiotic innovations. The parties will identify and designing probiotic bacteria that produce highly sustainable quantities of microbial metabolites known to improve human health and vitality.

二月初，Evogene 和 Verb Biotics 簽署了一項合作協議，以推進益生菌創新。雙方將鑑定和設計益生菌，以產生高度可持續數量的微生物代謝物，已知這些微生物代謝物可改善人類健康和活力。

The collaboration generates excellent synergy by combining Evogene knowledge in bacteria-based product development, utilizing its tech engine MicroBoost AI, with Verb Biotics access to the genomes of virus microbial strains that support the production of microbial metabolites with vital and human health.

此次合作將Evogene 在基於細菌的產品開發方面的知識相結合，利用其技術引擎MicroBoost AI，與Verb Biotics 獲取病毒微生物菌株的基因組，從而支持對人類健康至關重要的微生物代謝物的生產，從而產生卓越的協同效應。

This is a great example of the implementation of Evogene business model in which we leverage our technology in the new life sectors, not covered by the activity of our subsidiaries. We expect the collaboration to demonstrate the contributions of our unique technology to the fast growing field of human probiotics a sector estimated at $55 billion in 2022 and expected to reach $114 billion in 2031. We consider this collaboration as our first step in this lucrative market segment.

這是實施 Evogene 商業模式的一個很好的例子，我們在新生活領域利用我們的技術，而不是我們子公司的活動所涵蓋的領域。我們希望此次合作能展示我們獨特的技術對快速發展的人類益生菌領域的貢獻，該領域預計到 2022 年將達到 550 億美元，預計到 2031 年將達到 1,140 億美元。我們認為這次合作是我們在這個利潤豐厚的市場領域中邁出的第一步。

At the beginning of April, Evogene and the kitchen FoodTech hub by restaurant group teamed up to establish Finally, food and a driven company focused on sustainable protein production implants for the food sector.

4 月初，Evogene 與餐飲集團旗下的廚房 FoodTech 中心聯手成立了 Final, food and 一家專注於食品業可持續蛋白質生產植入的驅動型公司。

Finally Foods has secured pre-seed funding from The Kitchen Hub and the Israel Innovation Authority. Evogene holds approximately 40% stake in the company. This agreement will not require any financial contribution from Evogene, rather we expect that the agreement will generate future revenues for Evogene. We believe the conversion will demonstrate the potential of our technology to support the alternative protein market, estimated at $17.6 billion in 2022 and expected to reach $55 billion in 2032. We wish Finally Foods the best of success.

Final Foods 已獲得 The Kitchen Hub 和以色列創新局的種子前資助。Evogene持有該公司約40%的股份。該協議不需要 Evogene 提供任何財務貢獻，我們預計該協議將為 Evogene 帶來未來的收入。我們相信，此次轉換將展示我們的技術支援替代蛋白質市場的潛力，該市場預計到 2022 年將達到 176 億美元，預計到 2032 年將達到 550 億美元。我們祝福 Final Foods 取得最大成功。

I will conclude my update with a review of the main achievements made by our subsidiaries from the beginning of 2024. I would like to start with Casterra, Evogene fully owned subsidiary. With focus on developing an integrated solution to enable at-scale commercial cultivation of castor. Casterra Solution aim to address the global demand for stable castor oil supply, mainly for the biodiesel industry.

最後，我將回顧我們的子公司自 2024 年初以來的主要成就。我想從 Evogene 全資子公司 Casterra 開始。專注於開發整合解決方案，以實現蓖麻的大規模商業種植。Casterra 解決方案旨在滿足全球對穩定蓖麻油供應的需求，主要用於生質柴油產業。

As I mentioned, the company is utilizing GeneRator AI tech engine to direct and accelerate the development of its unique elite castor seed varieties in early 2023, Casterra entered into a frame supply agreement with E&I a leading oil and gas companies. Under the agreement, E&I has given Casterra purchase order last year, totaling $11.2 million. To date, Casterra has supplied only a small portion of the orders, mainly due to initial production challenges. Under the supervision of Casterra's new CEO, the company's recent engagement were seed growers in Africa and Brazil, are expected to provide approximately 900 tonnes in 2024, which is expected to fulfill all existing purchase order and provide additional inventory later this year.

正如我所提到的，該公司正在利用 GenRator AI 技術引擎來指導和加速其獨特的精英蓖麻種子品種的開發，並於 2023 年初與領先的石油和天然氣公司 E&I 簽訂了框架供應協議。根據協議，E&I 去年向 Casterra 發出了總額為 1,120 萬美元的採購訂單。迄今為止，Casterra 只供應了一小部分訂單，主要是由於最初的生產挑戰。在Casterra新任執行長的監督下，該公司最近的合作對像是非洲和巴西的種子種植者，預計在2024年提供約900噸，預計將履行所有現有採購訂單，並在今年稍後提供額外庫存。

It's anticipated that the balance of the existing purchase order will be delivered in the second half of 2024. I'm happy to share with you that Casterra is now building its backlog. Orders for 2025, Casterra, remains at the forefront of developing superior castor seed varieties with high yield, even under difficult growth conditions and with trade suitable for mechanized farming operations.

預計現有採購訂單的餘額將於2024年下半年交付。我很高興與您分享，Casterra 目前正在積壓訂單。到 2025 年，Casterra 的訂單仍然處於開發優質蓖麻種子品種的前沿，即使在生長條件困難的情況下，產量也很高，並且貿易適合機械化農業作業。

Now I would like to review our subsidiary AgPlenus, aiming to discover next-generation innovative protection products including herbicides, insecticides and fungicides and commercialize them through collaboration with world-leading partners. AgPlenus utilized Evogene's ChemPass AI tech engine to direct and accelerate its product development. Major agrochemical companies dominant today's crop protection industry still, they look to ag-tech companies to discover new target proteins and small molecules that inhibit such target protein, serving as the active ingredient in commercial crop protection products.

現在我想回顧一下我們的子公司AgPlenus，旨在發現包括除草劑、殺蟲劑和殺菌劑在內的下一代創新保護產品，並透過與世界領先的合作夥伴合作將其商業化。AgPlenus 利用 Evogene 的 ChemPass AI 技術引擎來指導和加速其產品開發。大型農化公司仍然主導著當今的作物保護產業，他們希望農業科技公司能夠發現新的目標蛋白和抑制此類目標蛋白的小分子，作為商業作物保護產品的活性成分。

AgPlenus is the company that addresses this need as shown by the two announcements made this past quarter on February 21, 2024, AgPlenus announced entering into a licensing and collaboration agreement with Bayer to develop a novel mode of action, broad-spectrum herbicide for farmers targeting the APTH1 protein discovered by AgPlenus under the agreement, AgPlenus will be entitled to receive an upfront payment.

AgPlenus 是一家滿足此需求的公司，如2024 年2 月21 日上一季發布的兩則公告所示，AgPlenus 宣布與拜耳簽訂許可和合作協議，為農民開發一種新穎的作用模式廣譜除草劑根據協議，AgPlenus發現的APTH1蛋白，AgPlenus將有權獲得預付款。

Ongoing research funding, milestone payments and royalties based on future product sales by will have the exclusive license for the development and commercialization of products under the collaboration on March 6, 2024, AgPlenus announced it has reached a milestone under its existing collaboration agreement with Corteva to develop new herbicides through a novel mode of action, APCO12, which was discovered by AgPlenus as well. In the next phase, the collaboration we focused on optimizing the herbicide candidates toward a commercial level product. These two collaboration agreements strength AgPlenus financial stability and overall positioning in the agriculture market.

持續的研究經費、里程碑付款和基於未來產品銷售的特許權使用費將於2024 年3 月6 日獲得合作產品開發和商業化的獨家許可，AgPlenus 宣布根據與Corteva 的現有合作協議，已達到一個里程碑，透過同樣由 AgPlenus 發現的新作用方式 APCO12 開發新的除草劑。在下一階段，我們的合作重點是優化除草劑候選產品，使其成為商業級產品。這兩項合作協議增強了 AgPlenus 的財務穩定性和在農業市場的整體定位。

I would like now to continue with the two subsidiaries using MicroBoost AI to accelerate and direct their product development, Lavie Bio and Biomica. Lavie Bio leveraged Evogene MicroBoost AI tech engine to develop next-generation ag-biological products. On February 20, 2024, Lavie Bio signed an agreement with Syngenta for the discovery and development of new biological insecticidal solution. The collaboration will leverage Lavie Bio, unique technology platform to rapidly identify and optimize bioinsecticide candidates.

我現在希望繼續使用 MicroBoost AI 來加速和指導兩個子公司 Lavie Bio 和 Biomica 的產品開發。Lavie Bio 利用 Evogene MicroBoost AI 技術引擎開發下一代農業生物產品。2024年2月20日，拉維生物與先正達簽署協議，共同發現開發新型生物殺蟲溶液。此次合作將利用 Lavie Bio 獨特的技術平台來快速識別和優化候選生物殺蟲劑。

On February 28, 2024, Lavie Bio also announced meeting Corteva's licensing agreement requirements, enabling the successful receipt of the second half advanced payment of $2.5 million from Corteva totaling $5 million. Additionally, Lavie Bio extended its joint validation trial with Bayer for its biofungicides following successful laboratory and greenhouse testing. The collaboration aims to address disease affecting fruit and vegetable worldwide.

2024年2月28日，Lavie Bio也宣布符合Corteva的授權協議要求，成功收到Corteva下半年預付款250萬美元，總計500萬美元。此外，在成功進行實驗室和溫室測試後，Lavie Bio 擴大了與拜耳生物殺菌劑的聯合驗證試驗。該合作旨在解決影響全球水果和蔬菜的疾病。

With positive results from the first year, Bayer proceeded to fill experiments for further validation. Also announced this quarter on March 13, Lavie Bio partnered with service global AgPlenus. We integrate it bioequivalent yellows into regenerative agriculture programs across the North America.

憑藉第一年的積極成果，拜耳繼續進行實驗以進行進一步驗證。Lavie Bio 也於本季於 3 月 13 日宣布與全球服務公司 AgPlenus 合作。我們將其生物等效的黃色納入整個北美的再生農業計劃。

This collaboration is aimed to enhance growing breadth is practical and offer tailored solution to support productivity and sustainability goals in the [AgPlenus] industry, particularly in segments like Springleaf, dual hub and boats. This announcement and other marketing and sales efforts for Yalos, Lavie Bio's first commercial micro-biobased product, support the penetration of Yalos in United States and Canada markets with additional crops being added for treatment. Based on initial orders and sales projections, we anticipated 2024 revenues for Yalos to increase compared to the previous year.

此次合作旨在增強實際的成長廣度，並提供量身定制的解決方案，以支持 [AgPlenus] 行業的生產力和永續發展目標，特別是在 Springleaf、雙輪轂和船舶等領域。這項公告以及 Lavie Bio 首款商業微生物產品 Yalos 的其他行銷和銷售工作，支持了 Yalos 在美國和加拿大市場的滲透，並添加了更多作物進行處理。根據最初的訂單和銷售預測，我們預計 Yalos 2024 年的收入將比前一年增加。

Now to Evogene subsidiary, Biomica, which specialized in developing microbiome best therapeutics for human health. On January 17, 2024, Biomica reached a significant milestone by completing Phase I trial enrollment for its microbiome best immuno-oncology throughout BMC 128, a rationally designed consortia of four bacteria. Biomica recently announced that it will be presenting preliminary Phase I study data of BMC128 in a poster presenting at the ASCO 2024 annual conference on June 3.

現在是 Evogene 子公司 Biomica，該公司專門開發微生物組對人類健康的最佳療法。2024 年 1 月 17 日，Biomica 完成了 BMC 128（一個由四種細菌組成的合理設計的聯合體）微生物組最佳免疫腫瘤學的 I 期試驗註冊，達到了一個重要的里程碑。Biomica 最近宣布，將在 6 月 3 日舉行的 ASCO 2024 年年會上以海報形式展示 BMC128 的初步一期研究數據。

Biomica is now preparing for advancing to Phase 2 of the clinical trial for BMC128 and already conducted a pre-IND meeting with the FDA aiming to initiate Phase II in 2025. In addition, results from Biomica's preclinical study in the IBS program conducted in collaboration with New York universities, medical school were presented at that the Digestive Disease week 2024 annual conference in May 2024.

Biomica 目前正在準備推進 BMC128 的臨床試驗第二階段，並已與 FDA 舉行了 IND 前會議，旨在於 2025 年啟動第二階段。此外，Biomica 與紐約大學、醫學院合作進行的 IBS 計畫臨床前研究結果在 2024 年 5 月舉行的 2024 年消化疾病週年會上公佈。

To summarize my part in this call, I would like to emphasize how proud I am of the achievements of Evogene and its subsidiaries to-date, reflected by the growing list of commercial and financial partners, the Evogene Group is engaged with.

為了總結我在本次電話會議中的作用，我想強調我對 Evogene 及其子公司迄今為止所取得的成就感到非常自豪，Evogene 集團合作的商業和金融合作夥伴不斷增多就反映了這一點。

During the last quarter, Lavie Bio announced partnering with two additional world-leading ad companies, Syngenta and Bayer. Casterra disclosed its engagement within E&I, a world-leading oil and gas company.

上季度，Lavie Bio 宣布與另外兩家世界領先的廣告公司先正達和拜耳合作。Casterra 揭露了與世界領先的石油和天然氣公司 E&I 的合作情況。

AgPlenus announced partnering with Bayer. And Evogene itself announced a new collaboration with Verb Biotics to advance human probiotic innovations and also establish together with the Kitchen Hub by Strauss Group, Finally Foods a new company focused on protein production in plant. No doubt, these are great achievement to start the year with.

AgPlenus 宣布與拜耳合作。Evogene 本身宣布與 Verb Biotics 建立新的合作，以推進人類益生菌創新，並與 Strauss Group 的 Kitchen Hub、Finally Foods 共同建立一家專注於植物蛋白生產的新公司。毫無疑問，這些都是新年伊始的偉大成就。

I will now hand over the call to Yaron, Evogene CFO, who will review our financial results for the first quarter of 2024.

我現在將把電話交給 Evogene 財務長 Yaron，他將審查我們 2024 年第一季的財務表現。

As of March 31, 2024 Evogene had consolidated cash, cash equivalents and short-term bank deposits of approximately $26.6 million compared to approximately $31.1 million from December 31, 2023. During the first quarter the consolidated cash usage was approximately $4.5 million. Excluding our two self-funding subsidiaries, Lavie Bio with a positive cash flow of approximately $0.3 million and Biomica with a cash usage of approximately $1.4 million, the cash usage of Evogene and the other subsidiaries was approximately $3.4 million.

截至 2024 年 3 月 31 日，Evogene 的合併現金、現金等價物及短期銀行存款約為 2,660 萬美元，自 2023 年 12 月 31 日起約為 3,110 萬美元。第一季綜合現金使用量約 450 萬美元。除去我們的兩個自籌資金子公司Lavie Bio（正現金流約30萬美元）和Biomica（現金使用量約140萬美元）外，Evogene和其他子公司的現金使用量約為340萬美元。

As Ofer already stated, our projected cash usage for 2024 excluding Biomica and Lavie Bio is approximately $8 million compared to $12.5 million in 2023, demonstrating a notable 36% decrease year-over-year. Revenues for the first quarter of 2024 were approximately $4.2 million compared to approximately $0.6 million in the same period the previous year. The revenue increase was primarily due to revenues recognized by Lavie Bio with a license agreement with Corteva and due to revenues recognized by AgPlenus for the new collaboration with Bayer during the first quarter of 2024.

正如 Ofer 已經指出的那樣，我們預計 2024 年（不包括 Biomica 和 Lavie Bio）的現金使用量約為 800 萬美元，而 2023 年為 1250 萬美元，比去年同期顯著下降 36%。2024 年第一季的營收約為 420 萬美元，而去年同期營收約為 60 萬美元。營收成長主要歸因於 Lavie Bio 與 Corteva 簽訂的授權協議確認的收入，以及 AgPlenus 在 2024 年第一季與拜耳的新合作確認的收入。

As Ofer stated, we anticipate continued revenue growth in 2024 compared to the previous year, mainly in the second half of 2024 based on Casterra's forecast for seed order supply. R&D expenses for the first quarter of 2024, which are reported net of non-refundable grants received were approximately $4.8 million and remained stable as compared to approximately $4.8 million in the same period in the previous year.

正如 Ofer 所說，根據 Casterra 對種子訂單供應的預測，我們預計 2024 年營收將比前一年持續成長，主要是在 2024 年下半年。2024 年第一季的研發費用（扣除已收到的不可退還贈款後的淨額）約為 480 萬美元，與去年同期的約 480 萬美元相比保持穩定。

Sales and marketing expenses were approximately $992,000 for the first quarter of 2024 and compared to approximately $800,000 in the same period the previous year. The increase is mainly due to increased sales and marketing activities in Casterra promoting its elite seed varieties and Lavie Bio promoting the sales of its first commercial product, Yalos.

2024 年第一季的銷售和行銷費用約為 992,000 美元，而去年同期約為 80 萬美元。這一增長主要是由於卡斯特拉（Casterra）推廣其優良種子品種的銷售和營銷活動增加，以及拉維生物（Lavie Bio）推廣其首款商業產品 Yalos 的銷售。

General and administrative expenses were approximately $1.7 million in the first quarter of 2024 compared to approximately $1.5 million in the same period in the previous year, mainly due to non-cash compensation to the subsidiary CEOs.

2024 年第一季的一般及管理費用約為 170 萬美元，而去年同期約為 150 萬美元，主要是由於對子公司執行長的非現金薪酬。

Following the decision to cease Canonic operations, we have recorded in other expenses, approximately $0.5 million in the first quarter of 2024 and mainly due to impairment of fixed assets. Operating loss for the first quarter of 2024 was approximately $4.1 million compared to approximately $6.8 million in the same period in the previous year.

在決定停止佳能營運後，我們在 2024 年第一季計入了約 50 萬美元的其他費用，主要是由於固定資產減損。2024 年第一季的營運虧損約為 410 萬美元，而去年同期約為 680 萬美元。

The decrease in operating loss is mainly due to the increased revenues. Financing income net for the first quarter of 2024 was approximately $241,000 compared to financing expenses net of approximately $230,000 in the same period in the previous year.

營業虧損減少主要是因為收入增加。2024 年第一季的融資收入淨額約為 241,000 美元，而去年同期的淨融資費用約為 23 萬美元。

This difference was mainly due to an increase in interest income and revaluation of convertible sales during the first quarter of 2024 as compared to the same period in the previous year. Net loss for the first quarter of 2024 was approximately $3.8 million compared to approximately $7 million in the same period in the previous year.

此差異主要是由於2024年第一季利息收入較上年同期增加以及可轉換銷售重估所致。2024 年第一季的淨虧損約為 380 萬美元，而去年同期淨虧損約為 700 萬美元。

The $3.2 million decrease in the net loss is mainly due to the increased revenues in the first quarter of 2024 and financial income, as mentioned above, which was partially offset by the onetime $519,000 of other expenses created by ceasing Canonic's operation.

淨虧損減少 320 萬美元，主要是由於 2024 年第一季的收入和財務收入增加（如上所述），部分抵消了佳能停止運營而產生的 519,000 美元其他費用。

I would now like to hand over the call to your operator for the Q&A session.

我現在想將電話轉接給您的接線生進行問答環節。

Thank you. Ladies and gentlemen, at this time we will begin the question-and-answer (Operator Instructions).

謝謝。女士們、先生們，現在我們將開始問答（操作員說明）。

Yes, first question is, are there any updates on Evogene CRISPR capabilities capability?

是的，第一個問題是，Evogene CRISPR 功能有任何更新嗎？

Hi, good morning, a good day, everyone this is Ofer speaking. As you know, we participate in a very important consortium that was focusing on developing our CRISPR technology, and we took a major role in this consortium. The technology that we establish in this consortium was the base for our collaboration announced late last year with them color in name developing genome editing technology for processing, it's rate. We also have internal activity here in the Evogene with respect to the CRISPR technology for plant.

大家好，早安，美好的一天，我是奧弗。如您所知，我們參與了一個非常重要的聯盟，該聯盟專注於開發我們的 CRISPR 技術，我們在聯盟中發揮了重要作用。我們在這個聯盟建立的技術是我們去年年底宣布的合作的基礎，他們的名字是開髮用於處理的基因組編輯技術，它的速度。我們在 Evogene 也進行了有關植物 CRISPR 技術的內部活動。

So yes, we’re active in this area. Yes, we’re also looking for opportunity to leverage the technology that we develop there. And when there will be specific news, we will be more than happy to disclose it to our investors.

所以，是的，我們在這一領域很活躍。是的，我們也在尋找機會利用我們在那裡開發的技術。當有具體消息時，我們將非常樂意向投資者披露。

The next question, how are your Casterra seed suppliers preparing today for harvest, which can support follow-on orders to in ENI in 2025?

下一個問題是，您的 Casterra 種子供應商今天如何準備收穫，這可以支援 2025 年 ENI 的後續訂單？

Yes. Hi everyone. Good afternoon or good morning and wherever you are. So in Brazil our seed suppliers are doing this for the second year. They all have the right equipment and everything is streamlined. We are visiting there periodically. One of our ergonomists just came back last week, another one is going next week. I visited the personally about one half months ago to make sure that everything is ready for harvest.

是的。大家好。下午好或早上好，無論您身在何處。因此，在巴西，我們的種子供應商已連續第二年這樣做。他們都擁有合適的設備，一切都很精簡。我們定期拜訪那裡。我們的一位人體工學專家上週剛回來，另一位人體工學專家將於下週前往。大約一個半月前，我親自拜訪了這裡，確保一切都準備好收穫。

In Kenya, which is turning to be our major seed supplying operation, we purchased costumer data not Northern Italy. It is being shipped next week out of Italy and we're arrive in time for harvest in Kenya. We're also shipping the [indiscernible] and seed processing equipment from India and China to set up our own logistical center and where we will deal clean sort and back the seeds all under Casterra.

在肯亞，這將成為我們主要的種子供應業務，我們購買的是客戶數據，而不是義大利北部。它將於下週從義大利運出，我們將及時抵達肯亞進行收穫。我們也從印度和中國運送[音訊不清楚]和種子加工設備，以建立我們自己的物流中心，在那裡我們將進行清潔分類並支援所有在卡斯特拉下的種子。

We're in the process of registering a local entity in Kenya, which will operate as above mentioned. Again, we are there. I personally visited each and any of our growers and the location for seed processing and at this point in time, we see envision no problems in the seed processing and harvest procedures.

我們正在肯亞註冊一家當地實體，該實體將以上述方式運作。再說一遍，我們在那裡。我親自拜訪了我們的每一位種植者和種子加工地點，目前，我們認為種子加工和收穫程序不會出現任何問題。

What considerations do you believe remain outstanding before ENI can place a follow-on order for castor seed to be delivered in 2025?

在 ENI 下達 2025 年交付蓖麻種子的後續訂單之前，您認為哪些因素仍需要考慮？

Yoash, can you take this question as well?

Yoash，你也可以回答這個問題嗎？

Sure. So we cannot comment at this point in time about 2025 orders. I will only say that we are deep into negotiations with clients for most ENI of course, on the different territories, which means Kenya and other African territories, some of the orders going directly to ENI in specific location.

當然。因此，我們目前無法對 2025 年訂單發表評論。我只想說，我們正在與客戶就大多數 ENI 進行深入談判，當然，在不同的領土上，這意味著肯亞和其他非洲領土，一些訂單直接發送到特定地點的 ENI。

Others are going through their main headquarters in Italy. We are negotiating with both. And as soon as we have clear orders, we will of course notify everybody.

其他人正在參觀他們位於義大利的總部。我們正在與雙方進行談判。一旦我們有明確的命令，我們當然會通知所有人。

Were 100% of the upfront payment from buyer to AgPlenus is realized in the first quarter. And do you expect the ongoing R&D funding milestone payments and royalties to allow AgPlenus to be a profitable on a go-forward basis.

買家向 AgPlenus 支付的預付款 100% 在第一季實現。您是否期望持續的研發資金里程碑付款和特許權使用費能讓 AgPlenus 繼續獲利？

Here with us, we have also Dan Gelvan, the new CEO of AgPlenus, which I'm very happy that you joined us at the beginning of this year. And I will ask him to take the lead and answer this question. So Dan, please?

和我們在一起的還有 AgPlenus 的新任執行長 Dan Gelvan，我很高興您在今年年初加入我們。我會請他帶頭回答這個問題。那麼丹，好嗎？

So thank you very much. As Yaron said, the full amount of the upfront payments were recognized by Evogene in this quarter. And to the second part of the question, the payments that we are receiving are a significant contribution to our revenues, and they are in addition to other revenue streams that we have from other collaborations.

非常感謝。正如 Yaron 所說，Evogene 在本季度確認了全額預付款。對於問題的第二部分，我們收到的付款對我們的收入做出了重大貢獻，而且它們不包括我們從其他合作中獲得的其他收入來源。

We are not yet cash positive from these. And we deny as we go along and we start to receive from these multiple collaborations, both the milestone payments and broads in the future, we will be cash positive. We continue to expand our collaborations in order to be self-sustainable in the short term, even before we start to receive significant revenue payments. Thanks.

我們還沒有從這些中獲得現金。我們否認，隨著我們的進展，我們開始從這些多重合作中收到里程碑付款和未來的廣泛付款，我們將擁有現金。我們繼續擴大合作，以便在短期內實現自我永續發展，甚至在我們開始收到大量收入之前。謝謝。

The next question, what is your confidence level in filling the $10 million castor seed order by year-end? And what will be the cadence of the filling of this order.

下一個問題是，您對於在年底前完成價值 1000 萬美元的蓖麻種子訂單的信心有多大？以及執行該訂單的節奏是怎樣的？

Yoash can you take this question as well?

Yoash你也可以回答這個問題嗎？

Yes. So as we notified, we envision production of at least 900 tons of seeds in 2024. So we will be able to fill all the open orders for 2024, 2023 and 2024. The cadence will be the major supply will start in August all the way through December, and will probably kick around October.

是的。正如我們所通知的，我們預計 2024 年種子產量至少為 900 噸。因此，我們將能夠履行 2024 年、2023 年和 2024 年的所有未結訂單。主要供應的節奏將是從 8 月開始一直到 12 月，並可能在 10 月左右開始。

The next question, a cash question. What amount of cash have you front-end invested to line up capacity for the 900 tonnes per castor. What amount of future investment will be needed?

下一個問題是現金問題。您前期投入了多少現金來保證每個腳輪 900 噸的承載能力。未來需要多少投資？

So I will take this question. This is something that Casterra is responsible for, but still I would answer it. So the reason need, of course when you build an inventory for ongoing capital and as I mentioned earlier, one of the things that we are doing in Evogene is investing our money in the places where we see high probability of success.

所以我會回答這個問題。這是Casterra負責的事情，但我還是會回答。因此，當然，當你為持續資本建立庫存時，正如我之前提到的，我們在 Evogene 所做的事情之一就是將我們的資金投資到我們認為成功可能性高的地方。

So one of the reasons is what we're planning to do is that part of the money that we are going to save from closing Canonic activity, is to invest in funding the ongoing capital needs of Casterra.

因此，原因之一是我們計劃要做的是，我們將從關閉佳能活動中節省的部分資金用於投資滿足卡斯特拉持續的資本需求。

So this is already all taken into account and we built it in a way that we can fund the needs for the inventory. And when we'll start to receive revenue from our partners, we are going to use it to build the inventory for next year. And since we are expecting to start to receive significant amount of money during the third quarter of this year. So we are going to build the inventory for 2025 actually starting in 2024.

因此，這一切都已經考慮在內，我們以一種可以滿足庫存需求的方式來建構它。當我們開始從合作夥伴那裡獲得收入時，我們將用它來建立明年的庫存。由於我們預計將在今年第三季開始收到大量資金。因此，我們實際上將從 2024 年開始建立 2025 年庫存。

So this is how we are going to fund our ongoing the need for ongoing capital at the beginning for this at the beginning of the first half of 2024, is going to be from Evogene Resources, part of it coming from closing Canonic.

因此，這就是我們將如何為 2024 年上半年年初的持續資金需求提供資金，資金將來自 Evogene Resources，其中一部分來自關閉 Canonic。

Second half, it will start also to be funded from revenue we are going to generate from the our existing partners. Because what we are trying to do is that to start 2024 with a nice level of inventory to supply the demand that we expected in 2025.

下半年，它也將開始由我們現有合作夥伴產生的收入提供資金。因為我們正在努力做的是，在 2024 年開始時擁有良好的庫存水平，以滿足我們在 2025 年預期的需求。

The next question are the 900 tons of castor seed supply in addition to the 400 tonne expansion you reported on your Q1 earnings call. Or is the total supply now 900 tons?

下一個問題是，除了您在第一季財報電話會議上報告的 400 噸擴張之外，還有 900 噸蓖麻籽供應。還是現在總供應量是900噸？

So the total supply is 900 tons.

所以總供應量是900噸。

The next question how much, if any of the $4.2 million in revenues were from sales, seed sales?

下一個問題是，如果 420 萬美元的收入來自種子銷售，那麼有多少收入？

As, I mentioned in my part, only a small portion from the orders we receive in 2023. Our delivered so from this. You can understand that only a small portion from the revenue from this quarter is the attribute from Terra activity there is there are some revenue coming from customer activity but it's a very modest compared to what we are expecting to see in the second half of 2025 as we already disclosed.

正如我在文章中提到的，這只是我們 2023 年收到的訂單的一小部分。我們由此而來。您可以理解，本季收入中只有一小部分是來自 Terra 活動的屬性，還有一些收入來自客戶活動，但與我們預計 2025 年下半年看到的收入相比，這一比例非常適中：我們已經透露了。

Next question, please address competition faced by your CBP platform?

下一個問題，請解決您的 CBP 平檯面臨的競爭？

So I would like to refer in general, to what why do we think that our technology is unique. I think that what we are doing in Evogene is that we are not just building a competitional technology. It's all guided and we build it together with a group of biologists and chemists that actually are coming with the programs they are facing and they know about which the industry is facing. And we are really trying to address these type of problems in using our technology.

所以我想概括地談談為什麼我們認為我們的技術是獨一無二的。我認為我們在 Evogene 所做的不僅僅是建立一種有競爭力的技術。這一切都是有指導的，我們與一群生物學家和化學家一起建造它，他們實際上是帶著他們面臨的項目而來的，他們知道這個行業面臨著哪些問題。我們正在努力解決使用我們的技術時遇到的此類問題。

And then when we are working with our partners, I think and also with our subsidiaries, this is bringing additional validation to the technology and also help us to improve the technology all the time. And I think, that the fact that in our company, and this is very rare to see it in other places, the fact that we have three tech engine one for genomics type of product, then microbials and then chemistry and we are all managing it under the same umbrella.

然後，當我們與合作夥伴以及我們的子公司合作時，這將為技術帶來額外的驗證，並幫助我們始終改進技術。我認為，在我們公司，這在其他地方很少見，我們擁有三個技術引擎，一個用於基因組學類型的產品，然後是微生物，然後是化學，我們都在管理它在同一把傘下。

This has put us in a very, very unique position because in biology, in Life Science in general, it's all connected. It's all connected, and you can just focus on one fragment from the big story.So I think this is what's unique Evogene technology. And you know what lets our partners to be the proof. I mean, the number of partners that we are working with is getting bigger and bigger.

這使我們處於一個非常非常獨特的位置，因為在生物學中，在整個生命科學中，一切都是相互關聯的。所有這些都是相互關聯的，您可以只專注於大故事中的一個片段。您知道是什麼讓我們的合作夥伴成為證明。我的意思是，我們合作的合作夥伴越來越多。

Actually, it's really the our first tier type of companies such as Corteva, Bayer, Syngenta, ICL and I think this is just the beginning. I believe that there will be more that we our subsidiary or even Evogene direct is going to work with. So I truly believe that we are offering something different from what exists today in the market.

事實上，這確實是我們的第一梯隊類型的公司，例如 Corteva、拜耳、先正達、ICL，我認為這只是一個開始。我相信我們的子公司甚至 Evogene direct 將會與更多的公司合作。因此，我堅信我們提供的產品與當今市場上存在的產品不同。

There are no further questions at this time. Mr. Haviv, would you like to make your concluding statements?

目前沒有其他問題。哈維夫先生，您願意做總結發言嗎？

Yes, I would like to say thank you for everybody for participating in this the analyst call. I think that we had a great first quarter in this year. We are looking forward to continuing to update you on the next achievement of our company and subsidiaries at the next analyst call. Thank you very much, and have a great day.

是的，我想感謝大家參與這次分析師電話會議。我認為今年第一季我們表現出色。我們期待在下次分析師電話會議上繼續向您通報我們公司和子公司的下一個成就。非常感謝，祝您有美好的一天。

Thank you. This concludes Evogene's First Quarter 2024 Results Investor Webinar. Thank you for your participation. You may go ahead and disconnect.

謝謝。Evogene 2024 年第一季業績投資者網路研討會到此結束。感謝您的參與。您可以繼續並斷開連線。